Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02226250
Other study ID # 2014-031
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 26, 2014
Est. completion date February 20, 2015

Study information

Verified date January 2021
Source Clinical Nutrition Research Center, Illinois Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective is to determine absorption profile of a sugar-based beverage on inflammatory mechanism by timing of beverage consumption relative to meal intake. Secondary objective is to determine absorption profile of a sugar-based beverage on oxidative and metabolic mechanism by timing of beverage consumption relative to meal intake. The results will be served as an internal reference or negative control group to compare with polyphenol containing studies from other studies. Each subject will receive 3 identical placebo drinks at each time points: fasting (0h), with standardized breakfast meal (2h), and 2 hours after the breakfast meal (4h). A planned size of 12 will be recruited into this part of the study. This study is a single-arm design utilizing a multiple sampling, and repeated measures paradigm to evaluate timing influence of consumption of sugar-based beverage associated acute effect on inflammatory markers.


Description:

A planned sample size of 12 will be recruited into the study. This study will require one initial screening visit, one pre-study visit, and 1 study visit. The study will take 1-2 weeks per subject to complete. The initial screening visit will provide subject informed consent document and determine subject eligibility through height and weight measurements, vital signs, blood glucose test (finger prick), and completion of a survey related to general eating, health, and exercise habits. If willing and eligible to participate, a 3-day food record (2 weekdays and 1 weekend day) will be instructed at initial screening visit and collected at a pre-study visit to assess subjects' baseline dietary intake pattern. After reviewing baseline food records, subjects will be instructed to avoid any berry products throughout the study and follow a strictly limited polyphenolic diet for 3 days prior to the study visit, while maintaining their usual diet pattern and physical activity. Prior to 10-hr study visit, a dinner meal will be provided the day before the study visit to control the second meal effect from the food and beverage intake of the night before the study visit. Subject will arrive at the study visit fasted for at least 10 hours, well hydrated and rested. Each study visit will require blood draws throughout the visit. After pre-study procedures (height, weight, waist circumferences, vital sign, and blood glucose measurements) , a registered nurse will place a catheter in subject's arm for the purpose of multiple blood sample collections and take the initial blood draw at fasting. Thereafter, blood sample collection will occur every 1 hour for the next 10 hours. During the 10-hr study visit, subject will drink one of 3 identical placebo drinks at fasting (right after fasting blood draw), 2nd placebo drink with the breakfast meal (2 hrs after fasting blood draw) and the 3rd placebo drink at 2 hours after the breakfast meal (4 hrs after fasting blood draw). Premenopausal female subjects will be studied during the follicular phase of their menstrual cycle because food intake tends to be more stable during the follicular phase (days 1-13) than during the luteal phase (days 14-28) when the rise in progesterone levels decrease satiety often resulting in increased intake.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date February 20, 2015
Est. primary completion date January 13, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age and older - Body Mass Index (BMI) range from 25 to 29.9 kg/m2; exception BMI 23 to 27.4 kg/m2 for Asian population - Nonsmoker - No clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease - Not taking any medications that would interfere with outcomes of the study, i.e. lipid lowering medications, anti-inflammatory drugs, or dietary supplements. - Able to provide informed consent - Able to comply and perform the procedures requested by the protocol Weight stable: not gained or lost weight +/- 5 kg in previous 3 months Exclusion Criteria: - Men and women who smoke - Past smokers: abstinence for minimum 2 years - Men and women with known or suspected food intolerance, allergies or hypersensitivity - Men and women known to have/diagnosed with diabetes mellitus - Men and women who have fasting blood glucose concentrations > 125mg/dL - Men and women who have blood pressure >140 mmHg/90 mmHg - Men and women with documented vascular disease, e.g., heart failure, myocardial infarction, stroke, angina, related surgeries. - Men and women with cancer other than non-melanoma skin cancer in previous 5 years. - Women who are known to be pregnant or who are intending to become pregnant over the course of the study - Women who are lactating - Taking medication or dietary supplements that may interfere with the outcomes of the study; e.g., antioxidant supplement, anti-inflammation, lipid lowering medication. Subjects may choose to go off dietary supplements (requires 30 days washout). - Men and women who have donated blood within 3 months of the screening visit and blood donors/participants for whom participation in this study will result in having donated more than 1500 milliliters of blood in the previous 12 months. - Men and women who are vegans - Substance (alcohol or drug) abuse within the last 2 years. - Excessive coffee and tea consumers (> 4 cups/d) - Men and women who do excessive exercise regularly or athlete - Unstable weight: gained or lost weight +/- 5 kg in previous 3 months - Women who are taking hormonal contraceptive

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
3 Placebo Beverages
Sugar beverage 2 hr before meal, with meal and 2 hr after meal

Locations

Country Name City State
United States Clinical Nutrition Research Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Clinical Nutrition Research Center, Illinois Institute of Technology

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in metabolic markers over 10 hours after sugar beverage consumption at different time points. The timing influence of sugar beverage consumption on metabolic markers (triglyceride, total cholesterol,ApoB, and insulin) in relative to meal intake (2 hours before a meal, with a meal, and 2 hours after a meal). 10 hr
Primary Changes in inflammation markers over 10 hours after sugar beverage consumption at different time points. The timing influence of beverage consumption on inflammation markers in relative to meal intake (2 hours before a meal, with a meal, and 2 hours after a meal). 10 hr Postprandial paradigm
Secondary Changes in oxidative stress markers over 10 hours after sugar beverage consumption at different time points. The timing influence of beverage consumption on oxidative stress (oxidized LDL) in relative to meal intake (2 hours before a meal, with a meal, and 2 hours after a meal). 10 hr
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1